MH & Associates Securities Management Corp ADV Purchases Shares of 17,598 Biogen Inc. $BIIB

Key Points

• MH & Associates Securities Management Corp ADV opened a new stake in Biogen, purchasing 17,598 shares in Q4 worth about $3.10 million, roughly 2.5% of its portfolio and its 18th-largest holding.
• Recent results and guidance: Biogen beat quarterly EPS estimates ($1.99 vs. $1.61) on $2.28B revenue and set FY2026 guidance of $15.25–$16.25 EPS (sell‑side consensus ~15.83), supporting positive analyst commentary amid mixed ratings.
• Ownership note: Insider Priya Singhal sold 2,660 shares (a ~24.9% reduction), while institutions own about 87.93% of BIIB and insiders just 0.18%, indicating heavy institutional ownership and limited insider exposure.

MH & Associates Securities Management Corp ADV purchased a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,598 shares of the biotechnology company's stock, valued at approximately $3,097,000. Biogen comprises approximately 2.5% of MH & Associates Securities Management Corp ADV's investment portfolio, making the stock its 18th biggest position.

Several other hedge funds also recently added to or reduced their stakes in BIIB. Accredited Wealth Management LLC boosted its position in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 185 shares in the last quarter. WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter worth about $32,000. True Wealth Design LLC boosted its stake in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 90 shares in the last quarter. GoalVest Advisory LLC purchased a new stake in shares of Biogen during the 4th quarter worth about $35,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 161 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company's stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by company insiders.

Biogen Stock Performance

BIIB opened at $179.90 on Thursday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The firm has a market capitalization of $26.40 billion, a PE ratio of 20.42, a PEG ratio of 2.37 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm's 50-day moving average price is $186.71 and its 200 day moving average price is $172.21.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts' consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm earned $3.44 EPS. Biogen's quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a multi‑target collaboration with Alloy Therapeutics to use Alloy’s AntiClastic™ antisense oligonucleotide (ASO) platform, giving Biogen broad access to RNA‑targeting discovery tools and accelerating its antisense pipeline — a clear pipeline/development positive that supports longer‑term growth prospects. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen
• Positive Sentiment: Analyst commentary and coverage pieces highlight Biogen’s strong history of quarterly earnings surprises and argue the company has the setup to beat estimates again — sentiment that tends to support short‑term buying ahead of results. Why Biogen (BIIB) Could Beat Earnings Estimates Again
• Neutral Sentiment: Healthcare peers were softer in recent trading sessions, which can weigh on biotech names broadly even when company‑specific news is positive; this is a market/sector headwind rather than a Biogen‑specific problem. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: RBC lowered its price target on BIIB from $233 to $213 while maintaining an Outperform rating — a downgrade to the target that could temper upside from some investors despite the continued positive rating. RBC Capital Adjusts Biogen Price Target
• Negative Sentiment: Commentary (The Motley Fool) notes Biogen’s first‑quarter operating expenses came in higher than some expected, which caused a recent pullback — higher near‑term spending could pressure margins and create volatility around upcoming results. Why Biogen Stock Got Mashed on Monday

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BIIB. Piper Sandler increased their target price on shares of Biogen from $157.00 to $177.00 and gave the stock a "neutral" rating in a research note on Monday, February 9th. BMO Capital Markets increased their target price on shares of Biogen from $165.00 to $196.00 and gave the stock a "market perform" rating in a research note on Friday, February 6th. Sanford C. Bernstein reissued a "market perform" rating on shares of Biogen in a research note on Monday, February 9th. TD Cowen increased their target price on Biogen from $175.00 to $215.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Biogen in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $207.54.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.